Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   GTCB - GTC Biotherapeutics - Deel 10

BioPharma« Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 10

Volgen
2.041 Posts
Pagina: «« 1 ... 94 95 96 97 98 ... 103 »» | Laatste | Omlaag ↓
  1. sappas 26 november 2007 18:07
    quote:

    SkySpam1 schreef:

    [quote=Beurs-kneus]

    www.marketwatch.com:80/news/story/sto...
    ATryn(R) - A Safe Drug Without Use of Donor Blood

    Last Update: 8:57 AM ET Nov 26, 2007Print E-mail Subscribe to RSS Disable Live Quotes
    [/quote]
    Zag hem zonet ook in m'n mailbox zitten,
    gaan ze het daar dan toch nogeens leren!!?

    "ATryn® is a new, exciting drug
    with interesting perspectives if it can be used
    for the treatment of other indications".

    $0.99
    110 K
    Sky alles wat goed is komt langzaam, soms erg langzaam maar het komt :-)

    Groetjes,

    Sappas
  5. [verwijderd] 26 november 2007 19:40
    quote:

    Beurs-kneus schreef:

    www.leo-pharma.com/41256A84002BE7FC/a...
    Mooi, mooi, zover zijn we intussen al,
    voorlopig in dit artikel nog niks over de kostprijs en het aantal patiënten.
    Alsmede nog geen verdere info betreffende de
    andere Europese landen?

    STILTE kan soms oorverdovend zijn!
  6. [verwijderd] 26 november 2007 20:00
    kostprijs ?

    U vraagt wij draaien !

    health.apmnews.com/story.php?numero=9220
    by Ailis Kane

    LONDON, Nov 21 (APM) – Leo Pharma has launched its recombinant antithrombin product ATryn in the UK for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency.

    The launch on Monday marks the first European launch of the first drug to be produced by a transgenic animal – in this case a goat. ATryn was developed by Leo's partner GTC Biotherapeutics and gained European approval under exceptional circumstances in August 2006.

    "It is the first ever medicine from transgenic biotechnology," said Jim Frater, Leo's marketing manager for clinical care. "It's on the borderline of amazing."

    Frater told APM that a launch in Ireland would follow shortly and the firm would roll out the product across Europe depending on commercial and product supply considerations. He said it should be available in selected European markets by the end of 2008.

    In the UK, ATryn's NHS list price will be 17,850 pounds (25,000 euros) for a pack of 10 vials. Frater said that the first two days of treatment would cost on average 2,000 pounds (2,800 euros) per day, but the overall cost of the treatment course of three days or more would vary depending on each patient.

    Once diagnosed, patients with the rare condition of congenital antithrombin deficiency must take a maintenance dose of warfarin to prevent the formation of blood clots. However, if they need to undergo surgery the warfarin must be stopped. Patients are instead given heparin activated by antithrombin during and after the surgery.

    In some European markets, a human blood product-derived version of antithrombin is available.

    Frater said that ATryn has advantages over the blood-derived version, including reducing the risk of infection by blood-borne diseases. While there is no evidence that anyone having taken human antithrombin has developed the prion disease Creutzfeldt-Jakob disease, there is theoretically a risk.

    In addition, patients on ATryn have their antithrombin levels maintained at 100% because the administration of the drug includes both bolus and continuous infusion of the product.

    FUTURE INDICATIONS

    Frater also indicated that Leo and GTC are working on potential additional indications for ATryn.

    The product is in a Phase III trial in pregnant women with congenital antithrombin deficiency who have a particularly high risk of developing thromboses. Frater said that bleeding complications and embolisms are leading causes of maternal death.

    The Phase III trial is due to be completed by the end of the year and the firm hopes to submit a regulatory filing to extend the indication by the end of next year or the beginning of 2009.

    ATryn is also in a Phase II trial for disseminated intravascular coagulation in association with severe sepsis, which is the widespread formation of clots within blood vessels.

    Leo licensed rights to ATryn for Europe, the Middle East and Canada in 2005 and GTC retains the rights elsewhere.

    GTC announced in September that the FDA had designated ATryn a "fast track product" entitled to accelerated FDA review for the hereditary antithrombin deficiency indication.

    One in 5,000 people has congenital antithrombin deficiency.

    ak/rw

    ailis.kane@apmnews.com
    [9220] 21/11/2007 13:46 GMT - INDUSTRY
  11. [verwijderd] 27 november 2007 19:54
    quote:

    ohmygod schreef:

    Tuurlijk, alles in de plus vandaag, behalve mijn biotechjes. Zo rood als een overrijpte tomaat.
    inderdaad wat een kutfonds, wat een gepruts, die hele bio-wereld is 1 grote schijtzooi.

    een serieuze belegger heeft helemaal niets te zoeken in deze branche.

    onzinnige beloftes die alleen maar kosten en niets opbrengen.

    moet je nou kijken, de dow bijna 10% in de plus en die boerderij van ons op 98 ct, zijnde 65 eurocenten.

    wij zijn veel meer waard dan pharming oreerde een jaar terug een nog over-enthousiaste tom niewberry, its a bargain at these prices.........

    de koers deed toen nog 1.17.

    stomme amerikcaan.

    mvg, domme Nederlander.
2.041 Posts
Pagina: «« 1 ... 94 95 96 97 98 ... 103 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Avantium 1,744 +0,04 +2,11%
WDP 20,560 +0,30 +1,48%
AZERION 1,694 +0,02 +1,44%
KPN 3,511 +0,04 +1,12%
EBUSCO HOLDING 0,800 +0,01 +1,07%
SIGNIFY NV 20,680 +0,20 +0,98%
JUST EAT TAKEAWAY 11,820 +0,11 +0,90%
Flow Traders 24,680 +0,20 +0,82%
CTP 15,940 +0,12 +0,76%
TKH 35,320 +0,26 +0,74%
Vopak 44,400 +0,28 +0,63%
Philips Koninklijke 26,080 +0,14 +0,54%
ArcelorMittal 24,340 +0,12 +0,50%
Wolters Kluwer 175,650 +0,85 +0,49%
Akzo Nobel 54,960 +0,26 +0,48%
Eurocommercial Properties 23,500 +0,10 +0,43%
UNILEVER PLC 55,640 +0,22 +0,40%
ADYEN NV 1.604,800 +5,20 +0,33%
HEIJMANS KON 30,950 +0,10 +0,32%
Wereldhave 14,580 +0,04 +0,28%
ABN AMRO BANK N.V. 15,955 +0,04 +0,22%
RELX 48,240 +0,10 +0,21%
ASR Nederland 47,270 +0,06 +0,13%
OCI 10,910 +0,01 +0,09%
Aperam 26,500 +0,02 +0,08%
Fagron 18,960 0,00 0,00%
Nedap N.V. 59,000 0,00 0,00%
RENEWI 9,630 0,00 0,00%
SBM Offshore 18,380 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
TomTom 4,190 -0,11 -2,56%
Fugro 14,800 -0,36 -2,37%
Alfen N.V. 14,050 -0,29 -2,02%
FASTNED 20,450 -0,40 -1,92%
AMG Critical Materials N.V. 13,660 -0,25 -1,80%
NX FILTRATION 2,800 -0,05 -1,58%
AALBERTS NV 33,300 -0,48 -1,42%
Corbion 22,340 -0,32 -1,41%
Air France-KLM 8,006 -0,11 -1,40%
JDE PEET'S 16,160 -0,22 -1,34%
ForFarmers 3,300 -0,04 -1,20%
Kendrion 10,160 -0,12 -1,17%
DSM FIRMENICH AG 95,300 -1,10 -1,14%
ASML 704,400 -8,00 -1,12%
BESI 119,350 -1,15 -0,95%
Sligro 10,560 -0,10 -0,94%
BAM 4,012 -0,04 -0,89%
THEON INTERNAT 13,780 -0,12 -0,86%
CM.COM 5,770 -0,05 -0,86%
Sif Holding 11,800 -0,10 -0,84%
Galapagos 21,840 -0,18 -0,82%
ALLFUNDS GROUP 5,020 -0,04 -0,79%
PROSUS 37,675 -0,27 -0,70%
ASMI 545,600 -3,80 -0,69%
Heineken 65,040 -0,44 -0,67%
Arcadis 53,200 -0,35 -0,65%
Brunel 9,220 -0,06 -0,65%
Van Lanschot Kempen NV 46,700 -0,25 -0,53%
UMG 26,960 -0,14 -0,52%
EXOR NV 91,650 -0,45 -0,49%
NN Group 42,900 -0,21 -0,49%
NSI 21,800 -0,10 -0,46%
PostNL 0,983 0,00 -0,46%
RANDSTAD NV 41,610 -0,19 -0,45%
ACOMO 17,920 -0,08 -0,44%
IMCD 149,000 -0,65 -0,43%
ASCX 1.239,86 -5,16 -0,41%
VASTNED 28,200 -0,10 -0,35%
Pharming 0,825 0,00 -0,30%
B&S Group SA 4,155 -0,01 -0,24%
Ahold Delhaize 34,830 -0,08 -0,23%
ING 16,014 -0,04 -0,22%
Accsys 0,522 0,00 -0,19%
INPOST 15,760 -0,03 -0,19%
AEX 918,19 -1,28 -0,14%
AMX 833,90 -1,16 -0,14%
Aegon 6,256 -0,01 -0,13%
Basic-Fit 23,860 -0,02 -0,08%
SHELL PLC 32,055 -0,02 -0,05%
vlag naam koers verschil relatief verschil
AEX 918,19 -1,28 -0,14%
AEX GR 3.601,76 -4,69 -0,13%
Germany40^ 21.505,70 0,00 0,00%
FTSE 100 8.576,06 +5,29 +0,06%
Europe50^ 5.264,59 0,00 0,00%
US30^ 44.533,20 -31,40 -0,07%
Nasd100^ 21.384,90 -181,60 -0,84%
US500^ 6.010,66 -26,98 -0,45%
Japan225^ 38.756,60 -362,10 -0,93%
VD-NEW 16,38 -0,86 -5,01%
#/^ Index indications calculated real time, zie disclaimer